| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| CDMO/CMO(元) | 267,071,145.94 | - | 280,521,656.33 |
| 技术服务费(元) | 26,075,401.59 | - | 5,139,261.54 |
| 制剂(元) | 73,359,233.20 | - | 167,632,795.55 |
| 医药原料药及中间体(元) | 681,173,479.77 | - | 377,271,253.31 |
| 定制类产品及技术服务(元) | - | 494,145,335.11 | - |
| 自主选择产品(元) | - | 1,128,661,864.69 | - |
| 营业成本(元) | |||
| CDMO/CMO(元) | 110,259,720.83 | - | 111,905,118.42 |
| 技术服务费(元) | 13,797,116.20 | - | 204,333.86 |
| 制剂(元) | 49,550,204.96 | - | 73,446,459.44 |
| 医药原料药及中间体(元) | 145,081,830.06 | - | 85,413,401.70 |
| 定制类产品及技术服务(元) | - | 216,368,059.07 | - |
| 自主选择产品(元) | - | 306,450,985.89 | - |
| 毛利(元) | |||
| CDMO/CMO(元) | 156,811,425.11 | - | 168,616,537.91 |
| 技术服务费(元) | 12,278,285.39 | - | 4,934,927.68 |
| 制剂(元) | 23,809,028.24 | - | 94,186,336.11 |
| 医药原料药及中间体(元) | 536,091,649.71 | - | 291,857,851.61 |
| 定制类产品及技术服务(元) | - | 277,777,276.04 | - |
| 自主选择产品(元) | - | 822,210,878.80 | - |
| 毛利率(%) | |||
| CDMO/CMO(%) | 58.72 | - | 60.11 |
| 技术服务费(%) | 47.09 | - | 96.02 |
| 制剂(%) | 32.46 | - | 56.19 |
| 医药原料药及中间体(%) | 78.70 | - | 77.36 |
| 定制类产品及技术服务(%) | - | 56.21 | - |
| 自主选择产品(%) | - | 72.85 | - |
| 收入构成(%) | |||
| CDMO/CMO(%) | 25.49 | - | 33.77 |
| 技术服务费(%) | 2.49 | - | 0.62 |
| 制剂(%) | 7.00 | - | 20.18 |
| 医药原料药及中间体(%) | 65.02 | - | 45.42 |
| 定制类产品及技术服务(%) | - | 30.45 | - |
| 自主选择产品(%) | - | 69.55 | - |
| 毛利构成(%) | |||
| CDMO/CMO(%) | 21.51 | - | 30.13 |
| 技术服务费(%) | 1.68 | - | 0.88 |
| 制剂(%) | 3.27 | - | 16.83 |
| 医药原料药及中间体(%) | 73.54 | - | 52.16 |
| 定制类产品及技术服务(%) | - | 25.25 | - |
| 自主选择产品(%) | - | 74.75 | - |